
Opinion|Videos|February 21, 2025
Stakeholder Management and Interoperability of Biosimilars
A panelist discusses how their institution implements robust safety protocols including distinct labeling, electronic health record alerts, and staff education to prevent dispensing errors when managing multiple biosimilars, while also conducting targeted educational outreach to address stakeholder concerns about interchangeability.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How is your institution managing the use of multiple biosimilars for the same reference product to avoid dispensing errors?
- How have providers, patients, and other stakeholders at your institution reacted to the interchangeability of biosimilars? What educational strategies have been utilized to share key information with these groups?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
1,700 sites closed, 77,000 fewer children received PEPFAR-supported treatment after PEPFAR disruption | IAS 2026
2
Payers lean on step therapy, formulary exclusions as IRA reshapes Part D benefit design
3
Redemplo cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia
4
Step therapy requirements drive up time, costs in DME patients | ASRS 2026
5
























